GATA binding protein 1 (GATA1) (GATA1)

GATA binding protein 1 (GATA1) is a foundational zinc-finger transcription factor essential for the development of erythroid, megakaryocytic, mast cell, and eosinophil lineages [1]. It binds to the consensus DNA sequence (A/T)GATA(A/G) to regulate the expression of genes critical for heme synthesis, globin production, and cell survival [2]. Mutations in GATA1 are strongly associated with various hematological disorders, including X-linked thrombocytopenia and Diamond-Blackfan anemia [3]. Notably, N-terminal truncating mutations in GATA1 are a hallmark of transient myeloproliferative disorder and acute megakaryoblastic leukemia in children with Down syndrome [4]. While direct pharmacological targeting of transcription factors remains challenging, GATA1 activity can be modulated through its interaction with co-factors like FOG1 or via proteasomal degradation pathways induced by immunomodulatory drugs [5, 7]. Current research explores GATA1 as a biomarker for disease progression and a potential target for small molecule modulation in myeloid malignancies [6].

Other names

GATA-1ERYF1GF-1NF-E1Erythroid transcription factor

Pharmacological modulation of GATA1 primarily involves the use of E3 ubiquitin ligase modulators to induce its proteasomal degradation or the development of small molecules that disrupt its binding to DNA or co-factors such as FOG1 [5, 7, 8].